Mark G. Kris, MD | Authors


Ramucirumab Used to Delay Relapse Following EGFR TKIs in EGFR+ NSCLC

July 12, 2019

Mark G. Kris, MD, discusses the importance of delaying relapse in patients with EGFR-positive non–small cell lung cancer. He shares the significance of the findings from the phase III RELAY trial, where the goal was to delay the time to relapse by adding ramucirumab to erlotinib.

An Expert's Thoughts on the FDA Approval of Durvalumab in Locally Advanced Lung Cancers

April 09, 2018

Mark G. Kris, MD, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the recent FDA approval of durvalumab (Imfinzi) for the treatment of patients with locally advanced, unresectable stage III non–small cell lung cancer.